
Ibrutinib with bendamustine and rituximab in R/R CLL/SLL: Final 5-year results from the Phase 3 HELIOS trial

Population: N = 578

Primary endpoint: Progression-free survival

Eligibility: Absence of 17p deletion





for ≤ 6 cycles









To PD or unacceptable toxicity

EFFICACY


5-year analysis

Median progression-free survival

Treatment arm **65 months**

p < 0.0001

Control arm 14 months



SAFETY

Most common TEAEs (any grade):

79% 60% 40%

Infection Neutropenia Diarrhea

Grade ≥ 3 TEAEs: 90%

Serious TEAEs: 69%

TEAEs leading to discontinuation: 20%